Caseware UK (AP4) 2023.0.135 2023.0.135 2024-03-312024-03-31The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.true2023-04-01falseNo description of principal activity42truefalse 10252277 2023-04-01 2024-03-31 10252277 2022-04-01 2023-03-31 10252277 2024-03-31 10252277 2023-03-31 10252277 c:Director1 2023-04-01 2024-03-31 10252277 d:FurnitureFittings 2023-04-01 2024-03-31 10252277 d:FurnitureFittings 2024-03-31 10252277 d:FurnitureFittings 2023-03-31 10252277 d:FurnitureFittings d:OwnedOrFreeholdAssets 2023-04-01 2024-03-31 10252277 d:ComputerEquipment 2023-04-01 2024-03-31 10252277 d:ComputerEquipment 2024-03-31 10252277 d:ComputerEquipment 2023-03-31 10252277 d:ComputerEquipment d:OwnedOrFreeholdAssets 2023-04-01 2024-03-31 10252277 d:OwnedOrFreeholdAssets 2023-04-01 2024-03-31 10252277 d:CurrentFinancialInstruments 2024-03-31 10252277 d:CurrentFinancialInstruments 2023-03-31 10252277 d:CurrentFinancialInstruments d:WithinOneYear 2024-03-31 10252277 d:CurrentFinancialInstruments d:WithinOneYear 2023-03-31 10252277 d:ShareCapital 2024-03-31 10252277 d:ShareCapital 2023-03-31 10252277 d:RetainedEarningsAccumulatedLosses 2024-03-31 10252277 d:RetainedEarningsAccumulatedLosses 2023-03-31 10252277 c:FRS102 2023-04-01 2024-03-31 10252277 c:AuditExempt-NoAccountantsReport 2023-04-01 2024-03-31 10252277 c:FullAccounts 2023-04-01 2024-03-31 10252277 c:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 10252277 2 2023-04-01 2024-03-31 10252277 e:PoundSterling 2023-04-01 2024-03-31 iso4217:GBP xbrli:pure

Registered number: 10252277










LARSA MEDICAL LIMITED








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 MARCH 2024

 
LARSA MEDICAL LIMITED
REGISTERED NUMBER: 10252277

STATEMENT OF FINANCIAL POSITION
AS AT 31 MARCH 2024

2024
2023
Note
£
£

Fixed assets
  

Tangible assets
 4 
1,318
893

  
1,318
893

Current assets
  

Debtors: amounts falling due within one year
 5 
8,677
18,115

Cash at bank and in hand
  
188,862
147,653

  
197,539
165,768

Creditors: amounts falling due within one year
 6 
(11,876)
(10,711)

Net current assets
  
 
 
185,663
 
 
155,057

Total assets less current liabilities
  
186,981
155,950

  

Net assets
  
186,981
155,950


Capital and reserves
  

Called up share capital 
  
1
1

Profit and loss account
  
186,980
155,949

  
186,981
155,950


Page 1

 
LARSA MEDICAL LIMITED
REGISTERED NUMBER: 10252277
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 MARCH 2024

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the income statement in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




................................................
Dr K Alkaisy
Director

Date: 21 November 2024

The notes on pages 3 to 6 form part of these financial statements.

Page 2

 
LARSA MEDICAL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

1.


General information

Larsa Medical Ltd is a private company limited by shares and incorporated in England and Wales, registration number 10252277. The registered office is Byway 8 Luppit Close, Hutton, Brentwood, Essex, England, CM13 2JU.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

 
2.2

Turnover

Turnover is recognised to the extent that it is probable that the economic benefits will flow to the Company and the turnover can be reliably measured. Turnover is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before turnover is recognised:

Rendering of services

Turnover from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of turnover can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.3

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
2.4

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

Page 3

 
LARSA MEDICAL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

2.Accounting policies (continued)

 
2.5

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.


 
2.6

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Fixtures and fittings
-
15%
Reducing balance
Computer equipment
-
33%
Straight line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.7

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.8

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.9

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Page 4

 
LARSA MEDICAL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

3.


Employees




The average monthly number of employees, including directors, during the year was 4 (2023 - 2).


4.


Tangible fixed assets





Fixtures and fittings
Computer equipment
Total

£
£
£



Cost or valuation


At 1 April 2023
876
2,565
3,441


Additions
-
935
935



At 31 March 2024

876
3,500
4,376



Depreciation


At 1 April 2023
150
2,398
2,548


Charge for the year on owned assets
109
401
510



At 31 March 2024

259
2,799
3,058



Net book value



At 31 March 2024
617
701
1,318



At 31 March 2023
726
167
893


5.


Debtors

2024
2023
£
£


Trade debtors
8,344
17,798

Prepayments
333
317

8,677
18,115


Page 5

 
LARSA MEDICAL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

6.


Creditors: Amounts falling due within one year

2024
2023
£
£

Trade creditors
2,600
-

Corporation tax
7,304
6,948

Other creditors
16
2,083

Accruals
1,956
1,680

11,876
10,711


 
Page 6